GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
by Zacks Equity Research
Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.
Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
by Zacks Equity Research
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study
by Zacks Equity Research
GSK announces positive data from the DREAMM-7 head-to-head phase III study evaluating Blenrep for second-line treatment of relapsed or refractory multiple myeloma. The study meets its primary endpoint.
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise
by Zacks Equity Research
Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.
Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
GSK (GSK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 15.60% and 6.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.
GSK (GSK) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, GSK (GSK) closed at $35.98, indicating a +0.5% shift from the previous trading day.
GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.
Novartis (NVS) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.
GSK (GSK) Stock Moves -1.04%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, GSK (GSK) stood at $36.29, denoting a -1.04% change from the preceding trading day.
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Zacks Equity Research
Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.
GSK (GSK) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $36.67, marking a +0.25% move from the previous day.
Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why
by Zacks Equity Research
Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.
Why GSK (GSK) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, GSK (GSK) closed at $37.56, indicating a +0.59% shift from the previous trading day.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
GSK (GSK) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
GSK (GSK) closed at $37.10 in the latest trading session, marking a +1.23% move from the prior day.